A woman I’ll call Helen came in for a routine blood pressure follow-up about eighteen months after she’d been started on a beta-blocker. She was doing well. But near the end of the appointment, almost apologetically, she mentioned that her eyes had been bothering her for much of that time. Burning. Grittiness. That maddening feeling that something is caught in your eye when there’s nothing there. She’d been using artificial tears, the brand her pharmacist suggested, and they helped, but only for twenty minutes or so before the symptoms returned.
Her prescriber had told her dry eye was common and to keep using the drops.
That was true. But there were several other things Helen hadn’t been told. Her beta-blocker was likely making her symptoms worse. The drops she’d been given addressed the watery layer of her tear film, but the real problem was probably with the oily layer, and aqueous drops don’t fix that. And the underlying cause, which no one had named, was likely meibomian gland dysfunction, which sounds complicated and is actually one of the most common eye conditions there is.
It’s a pattern I’ve covered in this column before, usually about a different part of the body. I’ve seen it with foot pain and with knee arthritis. Dry eye follows the same script. A common condition, a first-line recommendation that’s technically reasonable, and everything that would actually help left out. Which is frustrating, because the real treatments are not exotic or expensive. They’re just not explained.
What dry eye actually is
The tear film isn’t simply water. It has three distinct layers. The outermost is a lipid, or oily, layer produced by the meibomian glands, small glands embedded in the tissue of your upper and lower eyelids. Beneath that sits the aqueous layer, the watery portion produced by the lacrimal glands. The innermost layer is mucin, produced by cells on the surface of the eye, which helps the whole film spread evenly and adhere.
Dry eye develops when something disrupts this system. Either there isn’t enough aqueous fluid, or the tears that are produced evaporate too quickly. The first is called aqueous-deficient dry eye. The second, which is far more common, is called evaporative dry eye.
The treatment depends on which type you have. Most people who’ve been using drops for months without real relief don’t know which type they have, because nobody thought to explain it.
The meibomian gland problem
A study published in the journal Cornea in 2012 found that 86 percent of dry eye patients showed signs of meibomian gland dysfunction. These glands produce the oily layer that caps the tear film and prevents evaporation. When they function normally, a thin film of oil spreads across the surface of the eye with every blink. When they don’t, that seal breaks down. Tears evaporate faster. The ocular surface becomes unstable. Symptoms follow.
There are roughly 25 to 40 meibomian glands in the upper eyelid and another 20 to 30 in the lower. Over time, from chronic low-grade eyelid inflammation, changes in the composition of gland secretions, and reduced blinking frequency, these glands can become blocked or begin to atrophy. The secretions thicken. The gland openings plug. The oil layer thins.
When that happens, the artificial tear you reach for replaces water. Not oil. The tear film is still missing its outer protective layer. Evaporation continues. You apply more drops. The cycle repeats.
This is why so many people with dry eye feel like they’re managing an inevitable condition rather than treating one with an actual cause. They’re often using the right instinct with the wrong category of solution.
What else drives it
Several other factors contribute significantly, and the most common ones are things people don’t connect to their eyes.
Medications are the most frequently overlooked. Antihistamines, including both older sedating formulas and the newer non-drowsy versions, reduce tear secretion by blocking receptors that control fluid production in the lacrimal glands. Antidepressants, particularly SSRIs and tricyclic antidepressants, have similar effects. Beta-blockers, diuretics, certain antihypertensives, oral hormone therapy, anticholinergic drugs, and isotretinoin are all on the list. This doesn’t mean any of those medications are the wrong choice. But if your dry eye started or noticeably worsened around the time a new prescription was added, that connection is worth naming to your prescriber.
Screen time contributes in a way that’s physiological rather than speculative. When people focus on a screen, the blink rate drops from a normal 15 to 20 blinks per minute to somewhere between 5 and 7. Blinking is what spreads the tear film across the ocular surface. Reduce that by two-thirds for several hours a day and the consequences are predictable.
Systemic conditions matter too. Sjogren’s syndrome, an autoimmune condition that specifically targets moisture-producing glands, is one of the primary causes of aqueous-deficient dry eye. Rheumatoid arthritis, lupus, thyroid disease, and ocular rosacea, which often accompanies skin rosacea without being separately diagnosed, all show meaningful associations with dry eye. Low humidity, heating systems, air conditioning, and wind don’t cause dry eye on their own, but they accelerate tear evaporation in people who are already susceptible.
What doesn’t work
Standard artificial tears provide real temporary relief. The problem isn’t the drops themselves. It’s that most people don’t match the type of drop to their specific deficiency.
If your problem is evaporative dry eye from meibomian gland dysfunction, adding more aqueous fluid doesn’t address the missing oil layer. You may feel better briefly, then right back to where you were. There are drops formulated with a lipid component, designed to supplement or stabilize the oil layer. Brands like Systane Balance and Soothe XP contain lipid ingredients intended specifically for this. These exist, they’re sold over the counter, and they’re almost never the drops that get suggested first.
Preservatives are a second issue. The most common preservative in artificial tears, benzalkonium chloride, can damage the surface cells of the eye with repeated exposure. If you’re using drops more than three or four times a day, which many people with moderate dry eye need to do, preservative-free formulations in single-use vials are the right choice. Most people using preserved drops four or more times daily are doing their ocular surface a slow disservice, and nobody told them.
On omega-3 supplements: they’re marketed aggressively for dry eye, and the evidence doesn’t support them. The DREAM trial, published in the New England Journal of Medicine in 2018, was a large, well-designed randomized controlled study that found omega-3 supplementation no better than placebo for dry eye symptoms or objective signs. This isn’t what supplement companies will tell you. It is what the study showed.
Warm compresses and lid hygiene
For meibomian gland dysfunction, which is most cases, the most effective first intervention is also the simplest: a warm compress on the closed eyelids for eight to ten minutes, once or twice daily. The heat softens the thickened meibomian secretions and helps them flow with each blink. The compress needs to hold its temperature throughout, around 40 degrees Celsius, which a standard warm washcloth struggles to maintain. Dedicated heated eye masks hold temperature more consistently and are inexpensive.
Lid hygiene follows. Cleaning along the lid margin with a wet cotton swab or a commercial lid wipe removes the bacterial biofilm that accumulates there and can worsen meibomian gland function. The whole thing takes about two minutes and becomes routine quickly.
These are not placeholders while you wait for something more serious. They are the treatment, in most mild to moderate cases. Consistent warm compresses and lid hygiene, done daily for four to six weeks, produce measurable improvement in meibomian gland function in a meaningful percentage of patients. The people who dismiss them as too minor to bother with are often the ones who come back months later asking about prescription options.
Prescription treatments
When consistent self-care isn’t enough, the prescription options have solid evidence behind them.
Cyclosporine ophthalmic emulsion, the active ingredient in Restasis and now available in generic forms, was FDA-approved in 2003. It works by reducing T-cell-mediated inflammation in the lacrimal gland tissue, which allows the gland to function more normally over time. The critical thing to understand about cyclosporine is that it is slow. Most people don’t reach full benefit until they’ve been using it for three to six months, dosed twice daily. A lot of people stop at six or eight weeks, when they haven’t seen much change, and conclude it doesn’t work. That’s generally too early.
Lifitegrast, brand name Xiidra, approved in 2016, works through a different mechanism. It blocks an inflammatory pathway that activates T-cells on the ocular surface, targeting the chronic inflammation that underlies a significant portion of dry eye disease. Some people see improvement faster with lifitegrast than with cyclosporine, sometimes within two to four weeks rather than months. Also twice daily.
A newer option, perfluorohexyloctane, sold as Miebo and approved in 2023, is the most recent addition. Unlike cyclosporine and lifitegrast, which target inflammation, Miebo works on the lipid layer directly. It’s a water-free formula that stabilizes the tear film’s oil component and is specifically studied for evaporative dry eye from MGD. Dosed four times daily. Whether it’s a better fit than the others depends on which mechanism is driving your symptoms, which is one of several reasons a thorough ophthalmology evaluation matters.
Punctal plugs
The small drainage holes in the inner corners of your eyelids, called puncta, are where tears exit the eye and flow toward the nose. Punctal plugs are small devices, typically silicone, inserted into those openings to reduce drainage and keep tears on the ocular surface longer.
The procedure is done in an ophthalmologist’s office, takes a few minutes, and is usually painless. Temporary dissolvable plugs are sometimes placed first to confirm that slowing drainage helps before committing to permanent silicone ones. They’re generally placed in the lower puncta initially. Punctal plugs work alongside other treatments rather than replacing them, and they’re particularly useful when the problem involves tears not staying in contact with the eye long enough, regardless of how much is being produced.
When to see an ophthalmologist
For mild symptoms, trying lipid-layer or preservative-free drops along with warm compresses and lid hygiene for four to six weeks is a reasonable starting point. If that sequence works, it may be all you need.
An ophthalmologist can examine the meibomian glands directly with specialized equipment, assess the stability and composition of the tear film, look for underlying conditions, and offer the full range of treatments: prescription medications, punctal plugs, and in-office procedures including intense pulsed light therapy, which is FDA-cleared for MGD and has reasonable supporting evidence.
See an ophthalmologist if your vision is being affected, if you’re experiencing significant pain rather than discomfort, if over-the-counter approaches haven’t moved the needle after four to six weeks, or if symptoms are severe enough to affect daily life.
Dry eye is extremely common. It’s also, in many cases, substantially treatable. Those two facts coexist, and a lot of people are living in the gap between them without knowing they don’t have to.
Know what type you have. Know whether any of your current medications might be contributing. If you’ve been told to keep using drops that aren’t working, it’s entirely reasonable to ask what type of dry eye you have and what other treatments are available.
That’s not a difficult conversation. It’s just the one nobody had with Helen.
